Security Snapshot

SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share (SWTX) Institutional Ownership

CUSIP: 85205L107

13F Institutional Holders and Ownership History from Q1 2019 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

2

Shares (Excl. Options)

40,001

Price

$50.74

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, par value $.0001 per share
Symbol
SWTX
Shares outstanding
75,607,738
Price per share
$46.99
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
40,001
Total reported value
$2,179,047
Share change
-5,320
Value change
-$235,008
Number of holders
2
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SWTX - SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share is tracked under CUSIP 85205L107.
  • 2 institutions reported positions in Q4 2025.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 2 to 0 between Q4 2025 and Q1 2026.
  • Reported value moved from $2,179,047 to $0.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 2 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 85205L107?
CUSIP 85205L107 identifies SWTX - SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share (SWTX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD GROUP INC 9.6% $331,026,195 7,158,871 The Vanguard Group 31 Dec 2024
Hudson Bay Capital Management LP 5.2% $184,992,910 3,936,857 Hudson Bay Capital Management LP 30 Jun 2025
Deep Track Capital, LP 4.6% $160,025,357 3,460,756 Deep Track Capital, LP 31 Dec 2024
FMR LLC 1.7% $58,187,769 1,258,386 FMR LLC 30 Apr 2025
GOLDMAN SACHS GROUP INC 0% -93% $7,115 -$228,207,264 132 -100% THE GOLDMAN SACHS GROUP, INC. 30 Sep 2025

As of 31 Dec 2025, 2 institutional investors reported holding 40,001 shares of SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share (SWTX). This represents 0.05% of the company’s total 75,607,738 outstanding shares.

Institutional Holders of SPRINGWORKS THERAPEUTICS, INC. - Common Stock, par value $.0001 per share (SWTX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 0 $0 -$2,179,000 $46.99 0
2025 Q4 40,001 $2,179,047 -$235,008 $50.74 2
2025 Q3 45,321 $2,391,055 -$3,523,277,571 $46.99 4
2025 Q2 75,052,336 $3,527,065,482 +$106,385,453 $46.99 221
2025 Q1 73,697,303 $3,254,809,380 -$236,161,841 $44.13 304
2024 Q4 80,867,369 $2,921,793,248 -$118,091,155 $36.13 214
2024 Q3 80,746,495 $2,587,723,334 +$49,338,074 $32.04 224
2024 Q2 77,131,944 $2,905,842,857 -$85,605,108 $37.67 207
2024 Q1 78,252,813 $3,851,696,232 +$167,390,016 $49.22 215
2023 Q4 75,361,544 $2,751,027,541 +$377,734,473 $36.50 177
2023 Q3 68,463,334 $1,579,882,169 -$32,327,366 $23.12 146
2023 Q2 69,628,559 $1,822,205,095 +$89,779,420 $26.22 140
2023 Q1 66,260,215 $1,702,158,459 -$5,021,341 $25.74 146
2022 Q4 66,570,883 $1,728,050,586 +$78,211,361 $26.01 136
2022 Q3 63,366,577 $1,801,775,442 +$234,357,441 $28.53 143
2022 Q2 55,292,284 $1,362,389,164 +$60,440,902 $24.62 138
2022 Q1 49,432,959 $2,790,521,874 +$222,890,732 $56.44 131
2021 Q4 45,453,187 $2,817,721,092 +$26,758,911 $61.98 141
2021 Q3 45,080,155 $2,861,165,390 +$40,050,823 $63.44 139
2021 Q2 44,740,163 $3,687,111,174 +$75,214,918 $82.41 133
2021 Q1 43,923,797 $3,231,236,494 +$39,655,480 $73.57 135
2020 Q4 43,386,194 $3,146,822,308 +$421,342,946 $72.52 123
2020 Q3 37,429,094 $1,784,359,599 +$128,329,715 $47.67 91
2020 Q2 34,753,276 $1,459,633,432 +$82,304,857 $42.00 77
2020 Q1 32,985,223 $890,602,797 +$24,755,483 $27.00 68
2019 Q4 31,922,184 $1,228,678,977 +$28,086,854 $38.49 56
2019 Q3 31,217,200 $676,785,000 +$676,785,000 $21.68 43
2019 Q2 53,948 $4,446,000 $82.41 1
2019 Q1 53,948 $4,446,000 $82.41 1
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .